Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Daniel J. Farrugia"'
Autor:
Brian J. Gebhardt, MD, Joel Thomas, BA, Zachary D. Horne, MD, Colin E. Champ, MD, Daniel J. Farrugia, MD, PhD, Emilia Diego, MD, Gretchen M. Ahrendt, MD, Sushil Beriwal, MD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 3, Pp 258-264 (2018)
Purpose: The American College of Surgeons Oncology Group trial Z0011 demonstrated that axillary node dissection (ALND) can be omitted in patients managed with breast conserving surgery and 1 to 2 positive sentinel lymph nodes (SLNs) without adverse e
Externí odkaz:
https://doaj.org/article/de68aad0029447c6beea79839863c1a2
Autor:
Gretchen M. Ahrendt, Joel Thomas, Colin E. Champ, Daniel J. Farrugia, Emilia J Diego, Brian J. Gebhardt, Sushil Beriwal, Zachary D. Horne
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 3, Pp 258-264 (2018)
Advances in Radiation Oncology
Advances in Radiation Oncology
Purpose The American College of Surgeons Oncology Group trial Z0011 demonstrated that axillary node dissection (ALND) can be omitted in patients managed with breast conserving surgery and 1 to 2 positive sentinel lymph nodes (SLNs) without adverse ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e56545bb633057f0a8e35e59ccb0c08
http://www.sciencedirect.com/science/article/pii/S2452109418300629
http://www.sciencedirect.com/science/article/pii/S2452109418300629
Autor:
Li Zhu, Gretchen M. Ahrendt, Rachel C. Jankowitz, Emilia J Diego, Atilla Soran, Priscilla F. McAuliffe, Alessandra Landmann, Adam Brufsky, Ronald Johnson, David J. Dabbs, Beth Z. Clark, Rohit Bhargava, Daniel J. Farrugia, Shannon Puhalla
Publikováno v:
American Journal of Clinical Pathology. 150:34-42
Objectives Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods Human epidermal growth fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6072c32a0806c314ea126be495d882d
https://doi.org/10.1093/ajcp/aqy028
https://doi.org/10.1093/ajcp/aqy028
Autor:
Shannon Puhalla, Rohit Bhargava, Emilia J Diego, David J. Dabbs, Alessandra Landmann, Adam Brufsky, Beth Z. Clark, Rachel C. Jankowitz, Priscilla F. McAuliffe, Daniel J. Farrugia, Gretchen M. Ahrendt
Publikováno v:
American Journal of Clinical Pathology. 149:332-343
Objectives We hypothesized that prognostic accuracy of the residual disease in breast and lymph nodes (RDBN) method, which is calculated using residual tumor size, nodal involvement, and tumor grade, may be improved by incorporating residual tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f546ac26e25a47984d83f75c261cef
https://doi.org/10.1093/ajcp/aqx168
https://doi.org/10.1093/ajcp/aqx168
Autor:
Marguerite Bonaventura, Shannon Puhalla, Atilla Soran, Priscilla F. McAuliffe, Rohit Bhargava, Barry C. Lembersky, Daniel J. Farrugia, Alessandra Landmann, Ronald Johnson, Rachel C. Jankowitz, Beth Z. Clark, Adam Brufsky, G Ahrendt, David J. Dabbs, Nancy E. Davidson, Emilia J Diego
Publikováno v:
Cancer Research. 77:P6-09
Background: Patients achieving pathologic complete response to neoadjuvant chemotherapy have excellent disease free and overall survival. For patients with residual disease, the residual disease in breast and lymph node (RDBN) method provides useful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::601d1b05d7952269cfcfca508543bc96
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-14
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-14
Autor:
Alessandra, Landmann, Daniel J, Farrugia, Li, Zhu, Emilia J, Diego, Ronald R, Johnson, Atilla, Soran, David J, Dabbs, Beth Z, Clark, Shannon L, Puhalla, Rachel C, Jankowitz, Adam M, Brufsky, Gretchen M, Ahrendt, Priscilla F, McAuliffe, Rohit, Bhargava
Publikováno v:
American journal of clinical pathology. 150(1)
Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors.Human epidermal growth factor receptor 2-posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c57f70d4a94d835f3b5d25b5183b2bc9
https://pubmed.ncbi.nlm.nih.gov/29741562
https://pubmed.ncbi.nlm.nih.gov/29741562
Autor:
Rohit Bhargava, Li Zhu, Beth Z. Clark, Ronald Johnson, Daniel J. Farrugia, Alessandra Landmann, Gretchen M. Ahrendt, Adam Brufsky, David J. Dabbs, Marguerite Bonaventura, Emilia J Diego, Rachel C. Jankowitz, Atilla Soran, Priscilla F. McAuliffe, Shannon Puhalla, Barry C. Lembersky
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 30(8)
Magee Equations were derived as an inexpensive, rapid alternative to Oncotype DX. The Magee Equation 3 utilizes immunohistochemical and FISH data for estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 for its calculation (24.30812+ERI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c65c73be504a64881c1b4662aa8f1af
https://pubmed.ncbi.nlm.nih.gov/32661297
https://pubmed.ncbi.nlm.nih.gov/32661297
Autor:
Sunil R. Lakhani, Melissa A. Brown, Samantha Butler, Feng Lin, Diana Eccles, Amanda B. Spurdle, Bryony A. Thompson, David E. Goldgar, Sue Healey, Phillip J. Whiley, Leonard Da Silva, Logan C. Walker, Sheila A. Goff, Fergus J. Couch, Daniel J. Farrugia, Sean V. Tavtigian
Publikováno v:
Human Mutation. 31:E1484-E1505
Missense substitutions in high-risk cancer susceptibility genes create clinical uncertainty in the genetic counseling process. Multifactorial likelihood classification approaches and in vitro assays are useful for the classification of exonic sequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f60374f1584f2a4e701a3c256abf08c6
https://doi.org/10.1002/humu.21267
https://doi.org/10.1002/humu.21267
Autor:
I. D. Acu, Franca Stivala, Evanthia Galanis, Mark A. Schroeder, A B D'Assoro, M. M. Reinholz, Daniel J. Farrugia, Cosima Quatraro, Jeffrey L. Salisbury, Robert Busby, Cory Allen
Publikováno v:
Oncogene. 27:3901-3911
In this study, we establish an MCF-7 xenograft model that mimics the progression of human breast carcinomas typified by loss of p53 integrity, development of centrosome amplification, acquired estrogen receptor (ERalpha) heterogeneity, overexpression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e39aa9649a3ec4656bd8079fa50c5d
https://doi.org/10.1038/onc.2008.18
https://doi.org/10.1038/onc.2008.18
Autor:
Daniel J. Farrugia, Nicole Urban, Wataru Sakai, Fergus J. Couch, Céline Jacquemont, Mukesh K. Agarwal, Toshiyasu Taniguchi, Emily Villegas, Jake Higgins, Beth Y. Karlan, Cynthia Friedman, Elizabeth M. Swisher
Publikováno v:
Nature. 451:1116-1120
Ovarian carcinomas with mutations in the tumour suppressor BRCA2 are particularly sensitive to platinum compounds. However, such carcinomas ultimately develop cisplatin resistance. The mechanism of that resistance is largely unknown. Here we show tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b6e2f4edbd15f43b73d71868bf952ca
https://doi.org/10.1038/nature06633
https://doi.org/10.1038/nature06633